Financial Disclosure

HomeAboutIndustry Resources ▶ Financial Disclosure
Financial Disclosure

ATS Compliance with the Council of Medical Specialty Societies
Code for Interactions with Companies


The American Thoracic Society (ATS) Board of Directors adopted the Council of Medical Specialty Societies Code for Interactions with Companies (CMSS Code) in October 2010.  The CMSS Code Standard 2.2 states:

“Societies will disclose Company support (at a minimum Educational Grants, Corporate Sponsorships, Charitable Contributions, and support of Research Grants), making this information available to their members and the public.”

In compliance with the CMSS Code, the ATS is pleased to disclose annually all financial and in-kind relationships with companies that support or participate in ATS activities, which helps make what we do possible. Below, please find disclosures for the period of January 1, 2020 to December 31, 2020. Companies are listed alphabetically by level.


Educational Grants (Accredited and Independent Non-Accredited Education):

$1,000,000 and above:

  • GlaxoSmithKline

$500,000 to $750,000:

  • Boehringer Ingelheim Pharmaceuticals, Inc.

$250,000 to $499,999:

  • Actelion Pharmaceuticals US (Now Janssen)
  • Merck

$100,000 to $249,999:

  • AstraZeneca

$75,000 to $99,999:

  • Bayer Healthcare

$50,000 to $74,999:

$25,000 to $49,999:

Under $25,000:


Charitable Contributions:

$500,000 and above:

  • AstraZeneca LP, Boehringer Ingelheim Pharmaceuticals, Inc.

$250,000 - $499,000:  

  • None

$100,000 to $249,000:

  • Gilead Sciences
  • Sanofi Genzyme Corporation/Regeneron

$50,000 to $99,999:  

  • The Pfizer Foundation

Under $50,000:

  • National Board of Respiratory Care
  • The Francis Family Foundation


ATS Research Program Grants:

$100,000 to $249,000:

  • 4DMedical
  • GlaxoSmithKline
  • Mallinckrodt

$50,000 to $99,999:

  • CSL Behring


Exhibit, Industry Programs, and International Conference Advertising Revenue:

$100,000 to $174,999:

  • GlaxoSmithKline; Sanofi Genzyme Regeneron

$20,000 to $49,999:

  • 4DMedical; Actelion Pharmaceuticals US, Inc.; Amgen, Inc.; Gilead Sciences; Insmed Incorporated; Med Learning Group; Philips Healthcare; Takeda Pharmaceuticals

$10,000 to $19,999:

  • Biodesix; Fisher & Paykel Healthcare Inc; Galapagos BV; Jazz Pharmaceuticals; Vertex Pharmaceuticals, Inc.

$1 to $9,999:

  • Acceleron Pharma; Allergy & Asthma Network; Alliance of Sleep Apnea Partners; Auris Health; Bayer Healthcare; BD; Biofire Diagnostics, LLC; Bosch Healthcare Solutions GmbH; CH Technologies USA, Inc; CoapTech; COPD Foundation; Coreline Soft; CSL Behring; ECO MEDICS - ECO PHYSICS; eResearch Technology Inc. (ERT); Hermansky-Pudlak Syndrome; Hillrom; Medtronic; MGC Diagnostics; Monaghan Medical Corporation; Mylan Inc.; Perkin Elmer; Perma Pure LLC; PERT Consortium; Phaware Global Association; Polarean, Inc.; Pulmonary Fibrosis Foundation; Pulmonx Corp.; ResMed; STEMCELL Technologies Inc.; THORASYS Thoracic Medical Systems Inc; United Therapeutics Corporation; Veracyte; Vitalograph, Inc.; Vituity; ZEPHYRx


Collaborative Educational Programs:

$200,000 to $500,000+:

  • Actelion Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals Inc.; Merck & Co.; GlaxoSmithKline

$100,000 to $199,999:

  • None

$1 to $99,999:

  • Bayer Healthcare


ATS 2020 Corporate Membership Program:


  • Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals; Novartis Corporation; Sanofi Genzyme Regeneron; Theravance Biopharma; United Therapeutics Corporation; Vertex Pharmaceuticals, Inc.


  • Amgen Inc.; CSL Behring; Insmed, Inc.; Mallinckrodt Pharmaceuticals; Merck & Co.; Three Lakes Foundation; Viatris, Inc.


  • 4DMedical; Acceleron Pharma; Altavant Sciences; Bayer Healthcare; Bellerophon Therapeutics; Fisher&Paykel Healthcare; Galapagos NV; Jazz Pharmaceuticals; Teva Respiratory; Verona Pharma


  • Bristol-Myers Squibbs; Breath Therapeutics, A Zambon Company; Boston Scientific Corporation; Health Care Originals; Pieris Pharmaceuticals, Inc.; Pulmonx; Sunovion Pharmaceuticals; Veracyte; Vitalograph; Vivus;


ATS Journal and Other Non-Conference Advertising:

$200,000 and above:

  • AstraZeneca LP; Boehringer Ingelheim Pharmaceuticals, Inc.

$50,000 to $200,000:

  • Genentech, Inc.; Gilead Sciences; GlaxoSmithKline; New York Presbyterian Physician; RespirTech

$35,000 to $49,999:

  • Boston Medical Products; Merck & Co.

$15,000 to $34,999:

  • Actelion Pharmaceuticals; Ambu, Inc.; BioFire Diagnostics; Brigham & Women’s Hospital; Children's Hospital of Pittsburgh of UPMC; Insmed Incorporated; Jazz Pharmaceuticals; Mylan

$1 to $14,999:

  • American Academy of Sleep Medicine Foundation; Avanos; Beth Israel Lahey Health Physician Services; Beth Israel Medical Center; Bonefoam; Cedar Sinai Medical Center; Eve-Lab Formazione; Hartford Healthcare; Kalispell Regional Medical Group; Massachusetts General Hospital; MedScape Live; The National Disease Research Interchange; National Jewish Health; Northwestern Medicine; PeerView; Philips Trilogy; Physician’s Education Resource (PER); Pinnacle Health Group; Pulmonary Fibrosis Foundation; Rutgers University; Stemcell Technologies Canada; Temple University Health System – Digital; United Therapeutics; University of Virginia; US Department of Veterans Affairs; Veracyte; Vertex Pharmaceuticals


ATS Journal Non-Advertising Revenue (Reprints):

$30,000 and above:

  • Elsevier; C-Worth Data Service (Beijing) Company Ltd

$15,000 to $29,999:

  • GlaxoSmithKline

$1 to $15,000:

  • Dove Medical Press; GlaxoSmithKline; Content Ed Net; Jazz Pharmaceuticals; MW Office Gesellschaft


In Kind (Non-Monetary) Support (such as loan of equipment used in hands-on learning courses planned and controlled by the ATS):

  • None


All questions about the Society’s interactions with industry should be directed to Michelle Turenne – Chief of Development (